| 证券代码：002022 | 证券简称：科华生物 | | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 公告编号：2025-067 | 2025年第一次临时股东大会决议公告 上海科华生物工程股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、召开时间： （1）现场会议时间：2025年10月29日（星期三）下午14:30 （2）网络投票时间：2025年10月29日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为2025年10 月29日的交易时间，即9:15-9:25，9:30-11:30和13:00-15:00；通过深圳证券交 易所互联网投票系统投票的具体时间为2025年10月29日9:15-15:00期间的任意 时间。 2、召开地点：上海市徐汇区钦州北路1189号公司会议室 3、召集人：公司董事会 4、主持人：董事长李明先生 5、召开方式：本次股东大会采用现场投票 ...

上海科华生物工程股份有限公司 第十届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海科华生物工程股份有限公司（以下简称"公司"）第十届董事会第十八 次会议（以下简称"本次会议"或"会议"）通知于2025年10月24日以邮件方式 送达全体董事及高级管理人员，会议于2025年10月29日以现场结合通讯会议方式 召开。本次会议应参会董事9人，实际参会董事9人（包含3名独立董事）。本次 会议由公司董事长李明先生主持，会议的召开符合《中华人民共和国公司法》、 《上海科华生物工程股份有限公司章程》和《上海科华生物工程股份有限公司董 事会议事规则》的有关规定。 二、董事会会议审议情况 （一）审议通过《关于<2025年第三季度报告>的议案》 | 证券代码:002022 | | --- | | 债券代码:128124 | 证券代码：002022 证券简称：科华生物 公告编号：2025-069 债券代码：128124 债券简称：科华转债 表决结果：同意9票，反对0票，弃权0票。 （二）审议通过《关于公司及子公司使用自有资金进 ...

北京市金杜（广州）律师事务所 关于上海科华生物工程股份有限公司 2025 年第一次临时股东大会 之法律意见书 致：上海科华生物工程股份有限公司 北京市金杜（广州）律师事务所（以下简称本所）接受上海科华生物工程股 份有限公司（以下简称公司）的委托，根据《中华人民共和国公司法》（以下简称 《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、中国证券监督管 理委员会《上市公司股东会规则》（2025 年修订）（以下简称《股东会规则》）等 中华人民共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国 香港特别行政区、中国澳门特别行政区和中国台湾省）现行有效的法律、行政法 规、规章、规范性文件和现行有效的公司章程有关的规定，指派本所律师出席了 公司于 2025 年 10 月 29 日召开的 2025 年第一次临时股东大会（以下简称"本 次股东大会"），并就本次股东大会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1 1． 经公司 2024 年第一次临时股东大会审议通过的《上海科华生物工程股份 有限公司章程》（以下简称《公司章程》）； 2． 公司于 2 ...

Financial Performance - The company's revenue for Q3 2025 was ¥397,685,696.45, a decrease of 9.96% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥99,080,102.24, representing a decline of 42.20% year-on-year[5]. - The basic earnings per share were -¥0.1926, down 39.77% from the previous year[5]. - Total operating revenue decreased to ¥1,191,260,566.76 from ¥1,350,223,553.61, representing a decline of approximately 11.8% year-over-year[20]. - Net profit for the period was a loss of ¥253,819,970.95, compared to a loss of ¥106,928,544.45 in the previous period, indicating a significant increase in losses[21]. - Basic and diluted earnings per share were both reported at -0.4521, compared to -0.2413 in the previous period[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,170,207,077.81, a decrease of 1.26% from the end of the previous year[5]. - Total assets decreased to ¥5,170,207,077.81 from ¥5,236,128,052.84, reflecting a decline of approximately 1.3%[18]. - Total liabilities increased to ¥1,423,450,649.92 from ¥1,253,747,330.56, marking an increase of about 13.5%[18]. Cash Flow - Cash flow from operating activities for the year-to-date was -¥24,096,981.35, an improvement of 65.46% compared to the same period last year[11]. - Operating cash inflow for the current period was CNY 1,408,569,868.23, a decrease of 8.1% from CNY 1,533,401,815.74 in the previous period[22]. - Net cash flow from operating activities was CNY -24,096,981.35, an improvement from CNY -69,762,194.20 in the previous period[22]. - Cash inflow from investment activities totaled CNY 7,309,152.33, down significantly from CNY 177,920,867.58 in the previous period[22]. - Net cash flow from investment activities was CNY -89,058,866.50, worsening from CNY -4,694,494.96 in the previous period[22]. - Cash inflow from financing activities was CNY 380,789,640.48, an increase from CNY 121,361,311.96 in the previous period[23]. - Net cash flow from financing activities improved to CNY 121,170,122.91 from CNY -664,513,137.74 in the previous period[23]. - The ending cash and cash equivalents balance was CNY 867,784,574.93, slightly up from CNY 861,985,598.59 in the previous period[23]. - The company received CNY 378,539,640.48 in borrowings, a significant increase from CNY 118,075,216.96 in the previous period[23]. - Cash paid for operating activities was CNY 1,432,666,849.58, down from CNY 1,603,164,009.94 in the previous period[22]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 48,108[13]. - The largest shareholder, Zhuhai Baolian Investment Holding Co., Ltd., holds 13.64% of shares, totaling 70,147,179 shares[13]. - The company’s repurchased shares account for 2.66% of the total share capital, amounting to 13,696,600 shares[14]. - The top ten shareholders include both state-owned and private entities, indicating a diverse ownership structure[13]. - The company has signed a voting rights entrustment agreement with its controlling shareholder, affecting 10.64% of the voting rights[13]. Other Financial Metrics - The weighted average return on net assets was -3.11%, a decrease of 1.37 percentage points compared to the previous year[5]. - The company reported a significant increase in short-term borrowings, which rose by 270.91% to ¥309,419,850.98 due to operational needs[10]. - The company experienced a 412.77% increase in other comprehensive income, influenced by changes in the euro exchange rate[10]. - Investment income decreased by 87.70% to ¥1,056,127.82, attributed to lower returns from financial products compared to the previous year[10]. - The company reported a 75.74% increase in credit impairment losses, reflecting higher provisions for bad debts[11]. - Research and development expenses decreased to ¥114,226,587.57 from ¥147,599,126.10, a reduction of about 22.6% year-over-year[21]. - Other comprehensive income after tax was ¥25,828,113.66, compared to a loss of ¥1,734,692.20 in the previous period, indicating a recovery in this area[21]. Audit Information - The company did not undergo an audit for the third quarter financial report[24].

Core Viewpoint - The company emphasizes the importance of market capitalization management and acknowledges that stock prices are influenced by various factors beyond intrinsic value, including macroeconomic conditions, industry trends, and investor preferences [1] Group 1: Company Strategy - The company is committed to continuous high-quality development as the foundation for market capitalization management [1] - The company will focus on its core business and implement multiple measures to enhance operational efficiency and actively develop its business [1] - The company aims to improve its overall strength and intrinsic value through these efforts [1] Group 2: Compliance and Disclosure - The company will diligently implement its valuation enhancement plan and strictly adhere to information disclosure obligations as per relevant regulations [1]

Company Overview - Kewah Bioengineering Co., Ltd. is located at 1189 Qinzhu North Road, Xuhui District, Shanghai, established on November 22, 1981, and listed on July 21, 2004. The company specializes in the research, production, and sales of in vitro clinical immunodiagnostic reagents, in vitro clinical chemical diagnostic reagents, nucleic acid diagnostic reagents, genetic engineering drugs, and automated diagnostic instruments [1]. Financial Performance - As of June 30, 2025, Kewah Bio reported a revenue of 794 million yuan, a year-on-year decrease of 12.65%. The net profit attributable to shareholders was -133 million yuan, reflecting a significant year-on-year decline of 154.37% [2]. - Cumulative cash dividends since the A-share listing amount to 1.694 billion yuan, with 309 million yuan distributed over the past three years [3]. Stock Performance - On October 15, Kewah Bio's stock price increased by 2.04%, reaching 6.49 yuan per share, with a trading volume of 19.29 million yuan and a turnover rate of 0.58%. The total market capitalization stands at 3.338 billion yuan [1]. - Year-to-date, the stock price has risen by 2.85%, with a 1.41% increase over the last five trading days, a 3.85% decrease over the last 20 days, and a 0.76% decrease over the last 60 days [1]. Shareholder Information - As of June 30, 2025, the number of Kewah Bio shareholders is 42,200, a decrease of 0.84% from the previous period. The average number of circulating shares per person is 12,176, which has increased by 0.84% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the eighth largest, holding 2.5849 million shares, a reduction of 420,000 shares compared to the previous period [3]. Business Segmentation - The revenue composition of Kewah Bio includes 49.76% from agency products, 46.73% from self-produced products, and 3.51% from other sources [1]. - The company operates within the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics, and is involved in concepts such as gene sequencing, blood products, anti-influenza, pet economy, and monkeypox [1].

Group 1 - The company held its 17th meeting of the 10th Board of Directors on October 13, 2025, with all 9 directors present, including 3 independent directors [2][4] - The meeting approved the proposal to cancel the Supervisory Board, change the registered capital, and amend the Articles of Association, which will be submitted to the first extraordinary general meeting of shareholders in 2025 for special resolution [3][58] - The registered capital will increase from 514,317,177 yuan to 514,348,244 yuan due to the conversion of convertible bonds during the conversion period [58] Group 2 - The company plans to revise several management systems in accordance with the latest legal requirements, with some revisions requiring approval from the shareholders' meeting [5][38] - The company approved the renewal of the accounting firm Rongcheng Certified Public Accountants for the 2025 audit, pending authorization from the shareholders' meeting [39][52] - The first extraordinary general meeting of shareholders in 2025 is scheduled for October 29, 2025 [43]

Core Viewpoint - The company is convening its first extraordinary general meeting of shareholders in 2025 to discuss and approve the reappointment of the accounting firm, Rongcheng Certified Public Accountants, for the fiscal year 2025 [24][36]. Meeting Details - The extraordinary general meeting will be held on October 29, 2025, at 14:30, with both on-site and online voting options available [4][6]. - The record date for shareholders to attend the meeting is October 23, 2025 [7]. - The meeting will take place at the company's office located at 1189 Qinzhu North Road, Xuhui District, Shanghai [8]. Agenda Items - The meeting will review several proposals, including the reappointment of the accounting firm, which requires a special resolution with more than two-thirds approval from attending shareholders [9]. - The voting will be conducted separately for minority investors, ensuring transparency in the voting process [9]. Accounting Firm Information - Rongcheng Certified Public Accountants, established in 1988, is proposed for reappointment as the company's auditor for 2025 [25]. - The firm has a significant track record, with 1,549 registered accountants and a revenue of approximately 251 million yuan for 2024 [26]. - The firm has been involved in auditing 518 listed companies, with a total audit fee of about 62 million yuan for the same year [26]. Compliance and Approval Process - The reappointment of the accounting firm has been approved by the company's audit committee, board of directors, and supervisory board, all affirming the firm's independence and professional competence [35][36][37]. - The decision will take effect upon approval at the extraordinary general meeting [38].

Group 1 - The core point of the article is that Kehua Bio (SZ 002022) held its 17th meeting of the 10th board of directors on October 13, 2025, via telecommunication to discuss the proposal for the reappointment of the accounting firm [1] - For the first half of 2025, Kehua Bio's revenue composition is entirely from the bioproducts sector, accounting for 100.0% [1] - As of the time of reporting, Kehua Bio has a market capitalization of 3.3 billion yuan [1]

上海科华生物工程股份有限公司 募集资金管理制度 （2025 年 10 月修订） 第一章 总则 第一条 为了规范上海科华生物工程股份有限公司（以下简称"公司"）募 集资金的管理和使用，维护全体股东的合法权益，依据《中华人民共和国公司法》、 《中华人民共和国证券法》、《上市公司募集资金监管规则》、《深圳证券交易 所股票上市规则》（以下简称"《股票上市规则》"）、《深圳证券交易所上市 公司自律监管指引第 1 号——主板上市公司规范运作》和《上海科华生物工程股 份有限公司章程》（以下简称"《公司章程》"）等有关规定，制定本制度。 第二条 本制度所称募集资金，是指公司通过发行股票或者其他具有股权性 质的证券，向投资者募集并用于特定用途的资金，不包括公司为实施股权激励计 划募集的资金。本制度适用于上述募集资金的监管。 第三条 公司应当审慎使用募集资金，保证募集资金的使用与招股说明书或 者发行申请文件的承诺相一致，不得随意改变募集资金的投向。 公司应当真实、准确、完整地披露募集资金的实际使用情况，并在年度审计 的同时聘请会计师事务所对募集资金存放与使用情况进行鉴证。 募集资金投资项目通过公司的子公司或者公司控制的其他企业实 ...